BALCHEM CORP Form 10-Q May 05, 2014

FORM	10	\mathbf{C}
LOVIM	TO-	·V

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

(Mark One) Quarterly Report Pursuant to Section 13 or 15(d) of x the Securities Exchange Act of 1934

For The Quarterly Period Ended March 31, 2014

or

o Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ______ to _____

Commission File Number 1-13648

BALCHEM CORPORATION

(Exact name of registrant as specified in its charter)

Maryland 13-2578432

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number)

52 Sunrise Park Road, New Hampton, New York 10958 (Address of principal executive offices) (Zip Code)

845-326-5600

Registrant's telephone number, including area code:

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.

Yes b No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes b No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting

company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer b Accelerated filer o
Non-accelerated filer o Smaller reporting companyo

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

As of May 1, 2014 the registrant had 30,417,372 shares of its Common Stock, \$.06 2/3 par value, outstanding.

Part I. Financial Information Item 1. Financial Statements

BALCHEM CORPORATION

Condensed Consolidated Balance Sheets (Dollars in thousands, except per share data)

Assets Comment assets	March 31, 2014 (unaudited)	December 31, 2013
Current assets: Cash and cash equivalents	\$ 207,330	\$208,747
Accounts receivable, net of allowance for doubtful accounts of \$115 at March 31, 2014 and December 31, 2013	43,812	39,386
Inventories Prepaid expenses Prepaid income taxes Deferred income taxes Other current assets Total current assets	24,860 2,127 - 887 5,866 284,882	24,824 2,580 899 893 445 277,774
Property, plant and equipment, net	54,394	54,916
Goodwill Intangible assets with finite lives, net Other assets Total assets	28,515 14,158 501 \$ 382,450	28,515 15,126 541 \$376,872
<u>Liabilities and Stockholders' Equity</u> Current liabilities:		
Trade accounts payable	\$ 13,236	\$12,395
Accrued expenses	12,605	10,732
Accrued compensation and other benefits	2,273	4,770
Dividends payable	- 225	7,856
Income taxes payable Total current liabilities	225 28,339	35,753
	·	·
Deferred income taxes	5,931	5,884
Other long-term obligations Total liabilities	3,977	3,877
Total habilities	38,247	45,514
Commitments and contingencies (note 12)		
Stockholders' equity: Preferred stock, \$25 par value. Authorized 2,000,000 shares; none issued and outstanding Common stock, \$.0667 par value. Authorized 60,000,000 shares; 30,368,219 shares issued	-	-
and outstanding at March 31, 2014 and 30,225,763 shares issued and outstanding at	2,025	2,016
December 31, 2013	01 470	77 517
Additional paid-in capital	81,479 260,521	77,517 251,627
Retained earnings Accumulated other comprehensive income	260,521 178	251,627 198
recumulated office comprehensive meome	170	170

Total stockholders' equity 344,203 331,358

Total liabilities and stockholders' equity \$382,450 \$376,872

See accompanying notes to condensed consolidated financial statements.

2

BALCHEM CORPORATION

Condensed Consolidated Statements of Earnings (Dollars in thousands, except per share data) (unaudited)

	Three Months Ended March 31,	
	2014	2013
Net sales	\$85,995	\$84,651
Cost of sales	62,780	60,419
Gross margin	23,215	24,232
Operating expenses: Selling expenses Research and development expenses General and administrative expenses	4,189 773 4,898 9,860	4,287 838 3,242 8,367
Earnings from operations	13,355	15,865
Other expenses (income): Interest income Interest expense Other, net	(46) 1 28	(52) 1 53
Earnings before income tax expense	13,372	15,863
Income tax expense	4,478	4,975
Net earnings	\$8,894	\$10,888
Net earnings per common share - basic	\$0.30	\$0.37
Net earnings per common share - diluted	\$0.29	\$0.36

See accompanying notes to condensed consolidated financial statements.

3

BALCHEM CORPORATION

Condensed Consolidated Statements of Comprehensive Income (Dollars in thousands) (unaudited)

	Three Months Ended March 31, 2014 2013
Net earnings	\$8,894 \$10,888
Other comprehensive loss, net of tax:	
Net foreign currency translation adjustment	(18) (507)
Net change in postretirement benefit plan, net of taxes of \$1 for each of the three months ended March 31, 2014 and 2013	(2) (5)
Other comprehensive loss	(20) (512)
Comprehensive income	\$8,874 \$10,376
See accompanying notes to condensed consolidated financial statements.	
4	

BALCHEM CORPORATION

Condensed Consolidated Statements of Cash Flows (Dollars in thousands) (unaudited)

Three

Months

Ended